Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Scarpello, J. H.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes

John Hb Scarpello

Department of Diabetes and Endocrinology, City General Hospital, Stoke on Trent, ST4 6QG, UK, jhbscarpello{at}hotmail.com

Recently revised consensus targets for glycaemic management in patients with type 2 diabetes are challenging and require optimisation of dosing strategies for oral antidiabetic therapies. The demonstration of significant cardiovascular outcome benefits in metformin-treated type 2 diabetic patients enrolled in the United Kingdom Prospective Diabetes Study has established this agent as the first line oral therapy after diet failure in newly presenting overweight people with type 2 diabetes mellitus. The antihyperglycaemic efficacy of metformin increases with increasing daily doses between 500 mg and the upper limits of the recommended daily dosage ( ≥ 2000 mg/day). Although metformin is associated with gastrointestinal side-effects in up to 20% of patients, this is not generally dose related. Transient dose reduction, slower titration and taking the dose with meals may ameliorate the problem. Risk of lactic acidosis due to metformin is negligible when this agent is prescribed correctly, and is unrelated to the plasma metformin concentration. Intensification of metformin therapy within the dose range represents a rational and practical therapeutic strategy for optimising glycaemic control in patients who are suitable for, and tolerant of, metformin treatment. The recently introduced 1000 mg metformin tablet should facilitate the use of higher doses and may help treatment compliance.

Key Words: metformin • oral antidiabetic therapy • type 2 diabetes • dose-response relationships.

References

  • Stratton IM, Adler AI, Neil HAW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.[Abstract/Free Full Text]
  • European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • American Diabetes Association. Clinical Practice Recommendations. Diabetes Care 1999;22(Suppl 1):S1-114.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • New JP, Hollis S., Campbell F. et al. Measuring clinical performance and outcomes from diabetes information systems: an observational study. Diabetologia 2000;43:836-43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Krentz AJ, Ferner RE, Bailey CJ Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994;11:223-41.[Web of Science][Medline] [Order article via Infotrieve]
  • Bailey CJ Antidiabetic Drugs. Br J Cardiol 2000;7:350-60.
  • Schatz H. Preclinical and clinical studies on the safety and tolerability of repaglinide. Clin Exp Endocrinol Diabetes 1999;107(Suppl 4):S144-8.
  • Campbell IW, Howlett HC Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 1995;11(Suppl 1):S57-62.[Web of Science][Medline] [Order article via Infotrieve]
  • Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 1999;22:33-7.[Abstract/Free Full Text]
  • UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dandona P., Fonseca V., Mier A., Beckett AG Diarrhea and metformin in a diabetic clinic. Diabetes Care 1983;6:472-4.[Abstract]
  • Stades AM, Heikens JT, Holleman F., Hoekstra JB Effect of metformin on glycaemic control in type 2 diabetes in daily practice: a retrospective study. Neth J Med 2000;56:86-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Grant PJ The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996;19:64-6.[Abstract]
  • Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hermann LS, Schersten B., Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med 1994;11:953-60.[Web of Science][Medline] [Order article via Infotrieve]
  • McIntyre HD, Ma A., Bird DM, Paterson CA, Ravenscroft PJ, Cameron DP Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. Aust NZ J Med 1991; 21:714-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Cusi K., DeFronzo RA Metformin: a review of its metabolic effects. Diabetes Reviews 1998;6:89-131.[Web of Science]
  • Davidson MB, Peters AL An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997;102:99-110.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Garber AJ Using dose-response characteristics of therapeutic agents for treatment decisions in type 2 diabetes. Diabetes, Obesity and Metabolism 2000;2:139-47.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Campbell IW Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol 2000;7:625-31.
  • Leatherdale BA, Bailey CJ Acute antihyperglycaemic effect of metformin without alteration of gastric emptying. IRCS Med Sci 1986;14:1086-6.
  • Sambol NC, Chiang J., O'Conner M. et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996;36:1012-21.[Free Full Text]
  • Hollenbeck CB, Johnston P., Varasteh BB, Chen Y.-DI, Reaven GM Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes mellitus by glucose tolerance test criteria. Diabete & Metabolisme (Paris) 1991;17:483-9.
  • Jeppesen J., Chen Y.-DI, Zhou M.-Y, Reaven GM Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994;17:1093-9.[Abstract]
  • Turner RC, Millns H., Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS 23). BMJ 1998;316:823-8.[Abstract/Free Full Text]
  • Klein R., Klein BE, Moss SE, Cruickshanks KJ Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994;154:2169-78.[Abstract/Free Full Text]
  • Klein R., Klein BE, Moss SE, Cruickshanks KJ Ten-year incidence of gross proteinuria in people with diabetes. Diabetes 1995;44:916-23.[Abstract]
  • Haupt E., Knick B., Koschinsky T., Liebermeister H., Schneider J., Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab 1991;17:224-31.[Web of Science][Medline] [Order article via Infotrieve]
  • Scarpello JH, Hodgson E., Howlett HC Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med 1998;15:651-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cubeddu LX, Bonisch H., Gothert M. et al. Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors. Naunyn Schmiedebergs Arch Pharmacol 2000;361:85-91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bailey CJ Biguanides and NIDDM. Diabetes Care 1992;15:755-72.[Abstract]
  • Howlett HC, Bailey CJ A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489-503.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stang M., Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999;22:925-7.[Abstract]
  • Chan NN, Brain HPS, Feher MD Metformin-associated lactic acidosis: a rare or very rare clinical entity. Diabet Med 1999;16:273-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cusi K., Consoli A., DeFronzo RA Metabolic effects of metformin on glucose and lactate metabolism in non insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:4059-67.[Abstract/Free Full Text]
  • Fery F., Plat L., Balasse EO Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients. Metabolism 1997;46:227-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lalau JD, Race JM Lactic acidosis in metformin therapy: searching for a link with metformin in reports of `metformin-associated lactic acidosis'. Diabetes, Obesity and Metabolism 2000;2:1-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Lalau JD, Race JM Lactic acidosis in metformin therapy. Drugs 1999;58(Suppl 1):55-60.
  • Lalau JD, Race JM Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 1999;20:377-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bailey CJ, Turner RC Drug therapy: Metformin. N Engl J Med 1996;334: 574-9.[Free Full Text]
  • Brown JB, Pedula K., Barzilay J. et al. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998;21:1659-63.[Abstract]
  • Sulkin TV, Bosman D., Krentz AJ Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997;20:925-8.[Abstract]
  • Emslie-Smith AM, Boyle DIR, Evans JMM et al. Contraindications to metformin therapy in patients with Type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Holstein A., Nahrwold D., Hinze S., Egberts E-H. Contra-indications to metformin are largely disregarded. Diabet Med 1999;16:692-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Grant PJ, Stickland MH, Booth NA, Prentice CR Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 1991;8:361-5.[Web of Science][Medline] [Order article via Infotrieve]
  • Landin-Wilhelmsen K. Metformin and blood pressure. J Clin Pharm Ther 1992;17:75-9.[Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999;22:1125-36.[Abstract/Free Full Text]
  • Veehof L., Stewart R., Haaijer-Ruskamp F., Jong BM The development of polypharmacy. A longitudinal study. Fam Pract 2000;17:261-7.[Abstract/Free Full Text]
  • Paes AHP, Bakker A., Soe-Agnie S-J. Impact of dosage frequency on patient compliance. Diabetes Care 1997;20:1512-17.[Abstract]
  • Brown JB, Nichols GA, Glauber HS, Bakst A. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther 1999;21:1045-57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Morris AD, Brennan GM, Macdonald TM, Donnan PT Population-Based Adherence to Prescribed Medication in Type 2 Diabetes: A Cause for Concern. Diabetes 2000;49(Suppl 1):A76.
  • Menzies DG, Campbell I., McBain A., Brown IRF. Metformin efficacy and tolerance in obese non-insulin dependent diabetics: a comparison of two dosage schedules. Curr Med Res Opin 1989;11:273-8.[Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 1, No. 1, 28-36 (2001)
DOI: 10.1177/14746514010010010501
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Diabetes and Vascular Disease ResearchHome page
J. H. Scarpello and H. C. Howlett
Metformin therapy and clinical uses
Diabetes and Vascular Disease Research, September 1, 2008; 5(3): 157 - 167.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
J. A Ray, D. Huet, W. J Valentine, A. J Palmer, N. Cugnardey, and C. Renaudin
Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance(R)) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting
The British Journal of Diabetes & Vascular Disease, January 1, 2008; 8(1): 39 - 44.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
M. D Feher, M. Al-Mrayat, J. Brake, and K. S. Leong
Tolerability of prolonged-release metformin (Glucophage(R) SR) in individuals intolerant to standard metformin -- results from four UK centres
The British Journal of Diabetes & Vascular Disease, September 1, 2007; 7(5): 225 - 228.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Scarpello, J. H.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?